Evidence map›Paper›PMID 36039688›Full record

SynthesisEuropean journal of clinical investigation2022

Prognostic value of soluble urokinase-type plasminogen activator receptor in coronary artery disease: A meta-analysis.

Yang Li, Yaqun Ding, Yinjie Zhao, Yongqing Gui, Yajing Shen, Qiang Xiang

Open access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yang LiEmergency center, The First Affiliated Hospital of Army Medical University, Chongqing, China.
Yaqun DingEmergency center, The First Affiliated Hospital of Army Medical University, Chongqing, China.
Yinjie ZhaoEmergency center, The First Affiliated Hospital of Army Medical University, Chongqing, China.
Yongqing GuiEmergency center, The First Affiliated Hospital of Army Medical University, Chongqing, China.
Yajing ShenEmergency center, The First Affiliated Hospital of Army Medical University, Chongqing, China.
Qiang XiangEmergency center, The First Affiliated Hospital of Army Medical University, Chongqing, China.ORCID https://orcid.org/0000-0003-2205-9751
Army Medical University · CN

Funding

The Special Project for Improvement of Scientific and Technological Innovation Capabilities of Army Military Medical University 2021XJS18.
6 · The paper itself

Abstract

backgroundA potential inflammatory biomarker, soluble urokinase-type plasminogen activator receptor (suPAR) has been utilized to assist the prognostic assessment of coronary artery disease (CAD) patients; however, outcomes have been inconsistent. The prognostic relevance of suPAR as a predictor of CAD patient adverse outcomes was therefore examined.

methodsResearch articles published as of 1 January 2022 were retrieved from PubMed, Embase, the Web of Science and the Cochrane Library. All-cause mortality, cardiovascular mortality and other major cardiovascular events (nonfatal myocardial infarction, heart failure or stroke) were analysed as a subset of relevant studies' results. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for each study. The broad EQUATOR guidelines were conformed. Risk of bias was assessed with ROBINS-I tool.

resultsIn total, this analysis included nine studies including 14,738 CAD patients. All included studies made a correction for certain potential confounders. However, risk of bias ranged from moderate to critical. When the ROBINS-I tool was used. Patients with CAD that exhibited increased suPAR levels had a substantially higher risk of all-cause mortality (HR = 2.24; 95% CI 1.97-2.55) or cardiovascular mortality (HR = 2.02; 95% CI 1.58-2.58), but not of developing other major cardiovascular events (HR = 1.63; 95% CI 0.86-3.11). Considerable heterogeneity across studies was observed in our meta-analyses, but no significant publication bias was detected.

conclusionIn patients with coronary disease, suPAR may have prognostic value for both all-cause and cardiovascular mortality but not for other major cardiovascular events.

Indexed as

Coronary Artery DiseaseReceptors, Urokinase Plasminogen ActivatorBiomarkersHumansPrognosisProportional Hazards ModelsBiomarkersReceptors, Urokinase Plasminogen Activatorcoronary artery diseasemeta-analysisprognosissoluble urokinase-type plasminogen activator receptor

Identifiers

PMID36039688
PMCPMC9787755
OpenAlexW4293590184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.